Quote this publication Share Print

XEROQUEL

-
Opinions on drugs - Posted on Mar 19 2013

Reason for request

Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.

-


Clinical Benefit

Substantial

The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial.


Clinical Added Value

no clinical added value

XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication.


Contact Us

Évaluation des médicaments

See also